Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may be effectively targeted using MDM2 inhibitors. In the present study, we investigated the anticancer activity of the MDM2...

Descripción completa

Detalles Bibliográficos
Autores principales: Urso, Loredana, Cavallari, Ilaria, Silic-Benussi, Micol, Biasini, Lorena, Zago, Giulia, Calabrese, Fiorella, Conte, Pier Franco, Ciminale, Vincenzo, Pasello, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546476/
https://www.ncbi.nlm.nih.gov/pubmed/28562336
http://dx.doi.org/10.18632/oncotarget.17790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546476/
https://www.ncbi.nlm.nih.gov/pubmed/28562336
http://dx.doi.org/10.18632/oncotarget.17790

Ejemplares similares